Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

GLP-1 receptor agonists stories

Nov 11, 2026

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 2026·3 sources
00
Nov 9, 2026

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.

Nov 9, 2026·8 sources
00
Nov 8, 2026

Semaglutide improves cardiac structure and hemodynamics in heart failure with preserved ejection fraction

Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.

Nov 8, 2026·2 sources
00
Oct 28, 2026

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources
00
Oct 14, 2026

GLP-1 drugs reduce psychiatric hospital visits in schizophrenia patients with diabetes

A large US health records study found that people with schizophrenia taking GLP-1 drugs for diabetes had fewer psychiatric relapses and hospital admissions, suggesting potential mental health benefits beyond metabolic effects.

Oct 14, 2026·2 sources
00
Sep 8, 2026

GLP-1 drugs linked to reduced asthma and COPD attacks in new studies

New research shows that GLP-1 receptor agonists like semaglutide, commonly used for weight loss and diabetes treatment, are associated with fewer exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The findings are based on real-world patient data and add to growing evidence of respiratory benefits from these medications.

Sep 8, 2026·3 sources
00
Aug 5, 2026

Mounjaro Found to Reduce Heart Attack Risk by 33% in Type 2 Diabetes Patients with Heart Disease

A new study shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist drug, reduces heart attack risk by 33% when added to standard care for patients with both type 2 diabetes and existing heart disease. The findings come as worldwide sales of the drug doubled to £13.8 billion in the first half of 2026.

Aug 5, 2026·5 sources
00
Jul 23, 2026

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.

Jul 23, 2026·3 sources
00

Top claims

  • ▪In 2024, Blackstone Inc. reached an agreement to fund trials for Moderna Inc.’s influenza vaccine, which subsequently received U.S. regulatory approval in summer 2026
  • ▪Pfizer Inc. will maintain full ownership and operational control over the clinical development program for berobenatide under its funding deal with Blackstone Inc.
  • ▪Blackstone Inc. has expanded its involvement in co-funding clinical drug development trials in recent years

Subtopics

Clinical trials4Drug Policy, Pricing & Approval4GLP-1 medications4Drug Approval and Clinical Trials3Eli Lilly3Novo Nordisk3Cardiovascular diseases2GLP-1 / Weight-Loss Medications2Obesity treatment2Retatrutide2Weight loss drugs2Zepbound2Blood sugar & insulin1Cardiovascular health.1Clinical evaluation1Clinical Trial Design & Evaluation1Diabetes management1Drug development1Drug labeling & regulation1Drug safety1Drug safety & pharmacovigilance1FDA regulation1GLP-11GLP-1 drug side effects1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories